INTRODUCTION
Portal hypertension is the leading cause of morbidity and mortality in liver cirrhosis. Complications of portal hypertension in cirrhotic patients include esophageal and gastric varices, portal hypertensive gastropathy, ascites, hepatorenal and hepatopulmonary syndromes as well as portopulmonary hypertension [1] . At the time of diagnosis about 60% of cirrhotic patients have esophageal varices of different grades. In patients without varices, the rate of developing esophageal varices is about 5% annually. Acute variceal bleeding is a medical emergency and a life threatening event with a mortality rate of about 25% [2] .
Although 50% of all esophageal variceal bleeding episodes stop spontaneously, the rebleeding rate is high with about 50% of patients experiencing a second episode, usually within 2 weeks from the first episode. A second episode of bleeding puts the patient at a high mortality risk and is thus the reason for starting therapy as soon as possible [3] . Endoscopic sclerortherapy should be performed early after hospital admission, assuring that the patient is resuscitated and hemodynamically stable [4] . Endoscopic variceal sclerotherapy (EVS) effectively controls bleeding of esophageal varices (OV), however it has some adverse effects including post injection hemorrhage, chest pain, dysphagia and odynophagia [5] .
Proton pumps are located on the cytoplasmic membrane of gastric parietal cells. They create an acidic environment in the gastric lumen through exchanging one hydrogen ion for one potassium ion via the hydrogen/potassium adenosine triphosphatase enzyme system (the H + /K + ATPase pump) [6] . The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H + ions into the gastric lumen, making it an ideal target for inhibiting acid secretion [7] . Proton-pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They act by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system (the H + /K + ATPase, or, more commonly, the gastric proton pump) of the gastric parietal cells [6] . PPIs thereby inhibit both basal and stimulated gastric acid secretion, independent of the nature of parietal cell stimulus. They act through blocking acid secretion from all three pathways (neuronal, paracrine and endocrine) simultaneously, so they are considered the most potent medications used to reduce gastric acid secretion [8] .
Although all PPIs are effective in treatment of acid-related conditions, there are some differences in their clinical performance, regarding the degree and duration of gastric acid suppression [9] . Differences in PPIs hepatic metabolism may affect both efficacy and consistency, leading to small but significant variation in patient outcomes. PPI selection should therefore involve awareness of these relevant issues [10] . Acid suppressive therapy after EVS is advised as gastric acid may exacerbate post injection ulcers and delay healing [11] . Proton pump inhibitors (PPI) are the most potent pharmacologic agents for inhibition of gastric acid secretion. Therefore, these agents are the logical candidates to control the gastric acid injurious effects on post EVS complications [12] . However, some authors consider its use to be habit related and not evidence based [13] .
Aim of the work :
This study aims to evaluate the effects of rabeprazole administration for 8 weeks after endoscopic sclerotherapy for first attack variceal bleeding on the prevention and treatment of complications after EVS. Moreover, we aim to assess the presence of any adverse effects as a result of the use of this drug for this period in this specific patients group. Follow up of the patients by daily morning temperature which was recorded by the patients in a sheet for early prediction of portal bacteraemia and bacterial peritonitis along with other infections as pneumonia and infective diarrhea.
PATIENTS AND METHODS
Also the patients were also evaluated according to presence or absence of post-sclerotherapy symptoms including: epigastric pain, heart burn, retrosternal chest pain, dysphagia, dyspepsia, and odynophagea upon discharge and during the follow up visits every two weeks.
Patients used the non selective beta blocker (propranolol) for prevention of recurrent variceal bleeding, starting with 20 mg orally twice daily and increased to maximum tolerated dose or until heart rate reaches 55 beats per minute as recommended by the American association of the study of the liver disease [20] .
Then follow up of the patients every 2 weeks and for 2 month by upper GIT endoscopy with commenting on the variceal condition as previous, PHG, bleeding and development of sclerosant ulcer. Also follow up every 2 weeks for 2 months by CBC, and follow up of the patients' adverse symptoms as previous.
Follow up of the patient's physical state for the likely development or improvement of ascites, lower limb edema, jaundice, and hepatic encephalopathy (HE). And follow up for development of diarrhea, chest infection, and abdominal pain and tenderness as indicators for SBP.
Twenty seven patients were lost during the whole follow up period, 19 patients died and 8 patients were lost. Deceased and lost patients were replaced by other patients. Finally at the 8 th week 4 patients were lost at each group and were not replaced.
The follow up of the patients was done at the endoscopy unit, ICU and the in-patient department. The telephone was another way of contact with the patients.
Statistical analysis
Data were checked, entered and analyzed using SPSS version 19 EPI-INFO 6 for data processing and statistics. The quantitative data were presented as mean ( X ) and standard deviation and were compared using student t test. The categorical data were presented as number and percentage and were compared using Chi-square test (X 2 ). For all above-mentioned statistical tests done, the threshold of significance was fixed at 5% level (P-value).
RESULTS
There were no significant differences between the test group (group I) and the control group (group II) as regards mean age and gender distribution as shown in table (1) . Table ( 2) shows that, there are no statistically significant differences between cases and controls regarding the baseline clinical presentations including ascites, jaundice, hepatic encephalopathy, lower limb edema and fever. There were no statistically significant differences between group I and group II regarding all sonographic data e.g. liver size, portal vein diameter, presence and amount of ascites and spleen size as shown in table (3) . Table ( 4) shows that, there are no statistically significant baseline differences between cases and controls regarding laboratory parameters including (hemoglobin concentration, total leukocytic count, platelet count, albumin level, total and direct bilirubin levels), ALT, AST, PT, INR, and serum creatinine level. There was also no significant difference between the two groups as regards Child's grade as shown in table (5).
There were no significant differences found between the two groups as regards their preliminary endoscopic findings such as number of OV cords, grade of OV and risky signs, amount of sclerosant material used in sclerotherapy, grade of portal hypertensive gastropathy and duodenopathy as shown in table (6) . While Table (7) shows that, there are no statistically significant differences between cases and controls regarding post sclerotherapy symptoms including (dysphagia, odynophagia, retrosternal pain, epigastric pain, heart burn, and dyspepsia) after first endoscopic sclerotherapy setting. Table ( 8) shows that, there are no statistically significant differences between cases and controls regarding all three hematological parameters all through the follow up period.
There were no significant differences between the two studied groups as regards all the endoscopic findings such as risky signs, grade and number of OV cords, amount of sclerosant agents used to secure OV as well as portal hypertensive gastropathy and duodenopathy and frequency of sclerosant ulcer all through the period of follow up as shown in tables 9 and 10.
The incidences of post sclerotherapy symptoms such as dysphagia, odynophagia, heart burn, retrosternal and epigastric pain and dyspepsia were significantly lower in the test group than in the controls all through the period of follow up as shown in table (11) . There was also significant increase in the rate of moderate severity recurrent bleeding at the second week and at the end of the follow up period as shown in table (11) . There were no significant differences between the studied groups as regards incidence of ascites, lower limb edema, jaundice, abdominal tenderness, encephalopathy, fever, chest or urinary tract infections as shown in table (12) 
DISCUSSION
Esophageal variceal bleeding is a major cause of mortality in patients with portal hypertension. Endoscopic interventions, either by endoscopic variceal sclerotherapy or better by endoscopic variceal ligation are effective means of control of variceal bleeding [21] . Endoscopic intervention may be followed by ulcer formation, post injection sclerotherapy ulcer or post banding ulcer, that may be exacerbated by gastric acid. These ulcers may lead to further bleeding. Also endoscopic intervention is associated with annoying symptoms like chest pain, dysphagia and heart burn [5, 12] . Most of these symptoms are also induced by acid. This study was designed to evaluate the role of rabeprazole as a member of the PPI group in prevention of post sclerotherapy ulcer formation, recurrent bleeding and reduction of the post injection symptoms.
Rabeprazole was selectively used in this study as it is little different in its metabolism, being converted more rapidly to the activated sulphenamide and also dissociated more rapidly from the H + K + -ATPase, resulting in both a faster rate of inhibition and a shorter duration of action [22, 24] . Rabeprazole is also the PPI less affected by the hepatic CYP2C19 metabolism [23, 24] . Rabeprazole was used only for 2 months follow up period to avoid the development of long term use complications of PPIs like increased risk of bone fractures, anemia, and hypo-magnesemia and to limit the cost of the drug as much as possible.
All baseline demographic, clinical, laboratory, sonographic, endoscopic findings, symptoms after first EIS and the Child Pugh class had no statistically significant differences between the 2 groups. Moreover, in the present study there were no statistically significant differences regarding the CBC parameters of both groups during the 2 months follow up period. These results were in agreement with those reported by Dotan et al. [26] who evaluated 468 patients received pantoprazole and 468 controls for the development of thrombocytopenia and found no difference in the incidence of thrombocytopenia between both groups [25] .
In this study there were no statistically significant differences between cases and controls regarding endoscopic findings during the follow up period, no statistically significant differences between the two groups in the incidence of sclerosant ulcer development. These results were in concordance with that reported by Shaheen et al. [27] as they evaluated 42 patients after EVL and randomization into placebo and pantoprazole treated groups (pantoprazole 40 mg for 10 days). They found that subjects receiving pantoprazole after EVL had significantly smaller post-banding ulcers on follow-up endoscopy than subjects receiving placebo. However, the total ulcer number was not different between the groups [26] . Akahoshi et al. [28] also agree with the present study as they found that rabeprazole was associated with faster healing of post sclerotherapy ulcers [27] .
In this study there was statistically highly significant decrease in all post injection adverse symptoms in the rabeprazole treated group throughout the follow up period. These results were in agreement with that reported by Akahoshi et al. [28] who compared the results of using rabeprazole 20 mg once daily versus famotidine 20 mg twice daily and found that the H2-blocker group experienced a significantly higher number of days of heartburn and dysphagia than did the PPI group. Finally, they stated that rabeprazole treatment prevents sclerotherapy-associated gastroesophageal reflux and improves the subjective symptoms following EIS [27] . On the other hand, Shaheen et al. [27] used pantoprazole for 10 days on 42 patients and found no significant symptoms improvement and Boo et al. [29] who used pantoprazole for 7 and 14 days and found no significant difference in symptoms [26, 28] . This difference could be attributed to the use pantoprazole and the shorter duration of the two studies. Also, the two previously mentioned studies worked using band ligation which by nature has fewer symptoms than sclerotherapy.
In the present study, at the 2 nd and 6 th weeks of follow up, the incidence of moderate recurrent bleeding was significantly lower in the rabeprazole group, while the incidence of mild and severe recurrent bleeding and total cases with recurrent bleeding were not significantly affected. The total number of patients who developed recurrent bleeding at the end of the follow up period in the treated group was 7 versus 23 in the control group which was highly significantly lowered.
These results were in concordance with the studies conducted by Shaheen et al. [27] and Boo et al. [29] , in their studies 3 patients and 2 patients bled from post banding ulcer respectively all were in placebo group. The larger number of recurrent bleeding in the present work may be due to larger sample size and longer follow up period and the fact that sclerotherapy is done on patients with active variceal bleeding unlike banding which is done usually for primary prophylaxis [26, 28] .
At the end of our follow up period, there were no significant differences between both groups regarding the infectious or non infectious complications that can be induced by the use of rabeprazole. There was no significant difference regarding the development of fever, hepatic encephalopathy, SBP, diarrhea and chest infection. It was found that 32% of cases suffered from hepatic encephalopathy versus 26% of the controls. 14% of cases complained of one attack of chest infection versus 8% of controls and 2% of cases complained of 2 attacks of chest infection versus 0% of controls. 18% of PPI treated cases had one day of diarrhea versus 16% of controls, 14% of cases had 2 days of diarrhea versus 6% of controls, and 4% of cases had 3 days of diarrhea versus 2 % of controls. 57.1% of the admitted cases who had diagnostic follow up ascitic fluid aspiration had developed SBP with TLC of the ascetic fluid equals to or greater than 400 versus 50% of the controls. Conversely, Gipiuliano et al. [30] and Johnstone et al. [31] found increased risk of community acquired pneumonia with the PPI use; in this study no significant difference between both groups in risk of development of pneumonia [29, 30] . This difference may be due to short duration and single small dose of rabeprazole use in our study.
Deshpande et al. [32] and Howell et al. [33] found increased risk of colistridium difficile induced diarrhea associated with PPI use. However in this study no significant difference between both groups regarding diarrhea may be because not all cases of diarrhea with PPI use must be due to colistridium difficile infection, besides, in the present study the colistridium difficile toxin wasn't evaluated. Also Deshpande et al. [32] had used prophylactic antibiotics with PPI, which is also associated with increased risk of colistridium difficile diarrhea [31] . Howell et al. [33] used PPI daily or greater than daily dose and for longer duration than ours [32] .
In this study there was no significant difference between both groups regarding the incidence of development of SBP, unlike the study conducted by Bajaj et al. [34] in which the incidence of development of SBP in PPI group was 30% [33] . This difference may be due to larger population size, longer follow up period and concomitant use of antibiotics and the presence of a decompensated cirrhosis group in their study.
In this study no significant difference was found between the 2 groups regarding the development of hepatic encephalopathy, unlike the results recorded by Lin et al. [35] who found that patients with HE had a significantly higher rate of PPI use (89.1%) compared with non-HE patients (63.6%). The difference could be attributed to the larger sample size [34] . Also there were concomitant drug use as lactulose in the present work.
CONCLUSION
The use of rebeprazole at a dose of 20 mg daily after sclerotherapy can help controlling the post sclerotherapy adverse symptoms and reduce the risk of recurrent bleeding. These effects are not reflected on the endoscopical findings. This beneficial effect is mediated without significant increase of the risk of chest, gastrointestinal or ascetic fluid infections and without increasing the rate of hepatic coma.
